Skip to content
Disclosery

Flagship Pioneering, LLC

Follow

13F filer, CIK 1400240, CAMBRIDGE, MA

Flagship Pioneering, LLC reported $334,222,212 across 5 holdings for the quarter ended 2024-12-31, in a 13F-HR filed 2025-02-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-25-002708

Period
2024-12-31
Reported value
$334M
Holdings
5
Top 10 weight
100%
New
0
Sold out
1

Part of the filer group Flagship Pioneering, LLC

How groups are built

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
SYRSexited-1,293,849-$2.78M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2024

Share positions as resolved from 13F-HR 0000950123-25-002708, largest first. % of portfolio is the value over $334,222,212, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MRNAMODERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,632,149 shares; 2024Q4: 4,632,149 shares 4,632,149$193M57.63%0Timeline
FHTXFOGHORN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 12,674,120 shares; 2024Q4: 12,674,120 shares 12,674,120$59.8M17.9%0Timeline
SANASANA BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 25,001,856 shares; 2024Q4: 25,001,856 shares 25,001,856$40.8M12.19%0Timeline
OMEGA THERAPEUTICS INCOMEGA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 29,225,579 shares; 2024Q4: 29,225,579 shares 29,225,579$21.8M6.52%0
SERES THERAPEUTICS INCSERES THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 23,117,045 shares; 2024Q4: 23,117,045 shares 23,117,045$19.3M5.76%0

Sold out in Q4 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SYRSSYROS PHARMACEUTICALS INC COM1,293,849$2.78Mshares

How Q4 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-25-002708 base2025-02-14acceptance time not in the bulk data set